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To the Editor: In December 2014, a measles out-
break that had started at Disneyland Park in Anaheim, 
California, USA, and subsequently spread to numerous 
states garnered substantial media attention in the United 
States. In 2014, the US Centers for Disease Control and 
Prevention reported the highest number of measles cases 
(644) since the disease had been declared eliminated from 
the United States in 2000 (1). This number is still rela-
tively lower than the numbers reported from 30 countries 
of the European Union and the European Economic Area; 
the highest numbers of measles cases in 2013 were from 
the Netherlands (2,499 cases), Italy (2,216), the United 
Kingdom (1,900), and Germany (1,772) (2). There is 
widespread concern that increasing hesitancy to vaccinate 
in the United States might lead to outbreaks as large as the 
ones in Europe.
Measles vaccine is highly effective, and analyses of a 
large measles outbreak at a school in Germany have shown 
that receipt of >1 doses of vaccine can prevent infection in 
up to 99% of persons (3,4). One might therefore be tempted 
to think that the proportion of measles case-patients who 
had been vaccinated must be very small. However, when 
vaccination rates are high, most persons exposed to an in-
fected person will have received >1 doses of vaccine. As a 
consequence, the expected proportion of persons who had 
received >1 doses of vaccine among reported measles case-
patients will be substantially higher than 1%.
One can derive a simple quantitative relationship be-
tween vaccination coverage and the proportion of case-
patients who had been vaccinated. Assuming vaccination 
coverage of v and vaccine effectiveness of α, the propor-
tion of the population who are susceptible to measles in-
fection is 1 – αv. If all susceptible persons are at the same 
risk of getting infected, the proportion of vaccinated per-
sons among all case-patients will be v(1 − α)/(1 − αv). This 
equation is similar to the screening method that has been 
used to calculate vaccine effectiveness on the basis of the 
proportion of case-patients who were vaccinated and vac-
cination coverage (5). Perhaps somewhat counterintuitive 
at first, the proportion of vaccinated measles case-patients 
increases with vaccination coverage (Figure).
We hypothesized that the observed proportion of mea-
sles case-patients who had been vaccinated can be used to 
infer the vaccination coverage in a population at risk (Fig-
ure). To this end, we assume a vaccine effectiveness of 99% 
among persons who had received >1 doses (3,4). In 2013, 
countries in the European Union/European Economic Area 
reported 9,708 measles case-patients for whom vaccina-
tion status was known (2). Of those, 11.8% had received >1 
doses of measles vaccine. On the basis of the relationship 
derived above, this proportion corresponds to an expected 
vaccination coverage of 93.1% who had received >1 doses, 
which is consistent with reported numbers. Switzerland re-
ported 3,850 measles case-patients with known vaccination 
status from August 2006 through June 2009; of these, 7.0% 
had been vaccinated with >1 doses (8). The inferred vac-
cination coverage of 88.3% is very close to the reported 
national level of 87.0% for receipt of >1 doses at 2 years 
of age (8). In contrast, the most recent numbers from the 
United States suggest that vaccination coverage for receipt 
of >1 doses is still well over 90%.
Various complexities might affect the relationship be-
tween vaccination coverage in a community and the pro-
portion of case-patients who had been vaccinated. First, 
we assume a vaccine effectiveness of 99% among per-
sons who received >1 doses. Other estimates indicate that 
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Figure. Relationship between vaccination coverage with >1 
doses and the proportion of measles case-patients who had 
been vaccinated. The observed numbers of vaccinated case-
patients can be used to infer the vaccination coverage for different 
populations. Of 62 (21.0%) measles case-patients with known 
vaccination status in California, USA, 13 had received >1 doses 
(6). Of 230 (13.0%) case-patients with known vaccination status 
in the United States during January–May 2014, a total of 30 had 
received >1 doses (7). Vaccine effectiveness is assumed to be 
99% (3,4). The shaded areas for the countries of the European 
Union (EU) and European Economic Area (EEA), and Switzerland 
correspond to the 95% CIs. 95% CIs are omitted for California and 
the United States because of the small sample sizes.
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vaccine effectiveness is 92% for persons who received 1 
dose and 95% for those who received 2 doses (9). As-
suming that vaccine effectiveness is lower shifts the curve 
(Figure) to the left and would result in a lower estimate of 
vaccination coverage. Second, different numbers of per-
sons who received 1 and 2 doses complicate the identifi-
cation of overall vaccine effectiveness. Third, vaccination 
status is unknown for some measles case-patients. The 
proportion of nonvaccinated persons among those case-
patients might be higher than that among those known to 
be vaccinated, also leading to a lower estimate of vac-
cination coverage. Finally, nonvaccinated persons might 
be clustered together, and their risk for infection could 
be higher than that for the general population (10). This 
scenario would imply that the estimated vaccination cov-
erage does not reflect the general population but instead 
corresponds to a clustered subpopulation among whom 
vaccination rates are lower. The effects of these com-
plexities warrant further investigation. However, as the 
examples demonstrate, a model ignoring those effects is 
in good agreement with empirical data.
Our analysis suggests that the number of vaccinated 
measles case-patients should be closely followed through 
surveillance programs. A continuous decrease in the pro-
portion of measles case-patients who had been vaccinated 
over the years could indicate a decrease in vaccination rates. 
Conversely, an increase in the proportion of measles case-
patients who had been vaccinated would demonstrate the ef-
fectiveness of ongoing efforts to increase vaccination rates 
and could serve as a benchmark toward measles elimination.
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To the Editor: Lassa fever is a zoonosis caused by 
Lassa virus (LASV; family Arenaviridae, genus Lassavi-
rus). The primary reservoir of LASV is the multimammate 
rat (Mastomys natalensis), which is found throughout sub-
Saharan Africa. LASV outbreaks among humans occur 
only in West Africa in 2 noncontiguous areas: 1 in Guinea, 
Liberia, and Sierra Leone; and 1 in Nigeria. Rare cases and 
evidence of exposure of humans have been documented 
in neighboring countries (i.e., Benin, Burkina Faso, Côte 
d’Ivoire, Ghana, Mali, and Togo) (1). LASV RNA has been 
detected in only 4 patients: 1 in Germany who had trav-
eled in Burkina Faso, Côte d’Ivoire, and Ghana (2); 1 in the 
United Kingdom who had returned from Mali (3); and 2 in 
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